Editor-in-Chief Hatice Kübra Elçioğlu Vice Editors Levent Kabasakal Esra Tatar Online ISSN 2630-6344 Publisher Marmara University Frequency Bimonthly (Six issues / year) Abbreviation J.Res.Pharm. Former Name Marmara Pharmaceutical Journal
Marmara Pharmaceutical Journal 2017 , Vol 21 , Issue 2
Development and Validation of a Reversed-Phase HPLC Method for the Determination of Lisinopril and Gliclazide in Pharmaceuticals
Sevil Şenkardeş1,Tuğçe Özaydın2,Timuçin Uğurlu2,Ş. Güniz Küçükgüzel1
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Haydarpaşa, 34668 İstanbul, Turkey
2Department of Pharmaceutical Technology, Faculty of Pharmacy, Marmara University, Haydarpaşa, 34668 İstanbul, Turkey
DOI : 10.12991/marupj.300842 The aim of the present study was to develop and validate a High-Performance Liquid Chromatography (HPLC) method for the determination of lisinopril and gliclazide. The method was developed on Zorbax C8 analytical column (4.6x250 mm; 5μm) by isocratic elution with a flow rate of 1.0 mL/min and injection volume of 25 μl. The mobile phase composition was methanol:water (65:35 v/v, pH adjusted to 3.0 triethylamineorthophosphoric acid buffer) and the retention time was found to be 2.883 and 7.456 min for lisinopril and gliclazide, respectively. The developed method was found to be linear in the concentration range of 5-20 μg/mL for lisinopril and 15-60 μg/mL for gliclazide. The method was validated for linearity, accuracy, precision, LOD and LOQ. This developed procedure was succesfully applied conveniently for the analysis of lisinopril and gliclazide in pharmaceutical preparations. Keywords : Combined dosage forms, gliclazide, lisinopril, RPHPLC, method validation
Marmara University